Eastman Chemical Company vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 70)

Eastman Chemical Company

LeaderManufacturing

Enterprise

Kingsport TN specialty chemicals (NYSE: EMN) at record $9.38B 2024 revenue, adjusted EPS $10.80 (+18%); Tritan copolyester (Nalgene/BPA-free), LLumar films, molecular recycling platform for CPG sustainability competing with Celanese.

AI VisibilityBeta
Overall Score
B70
Category Rank
#17 of 290
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
69
Perplexity
73
Gemini
65

About

Eastman Chemical Company is a Kingsport, Tennessee-based global specialty materials, chemicals, and fibers company — publicly traded on the New York Stock Exchange (NYSE: EMN) as an S&P 500 Materials component — producing advanced materials, chemical intermediates, and specialty fibers for transportation, building and construction, consumer products, and agricultural markets through approximately 14,000 employees in 9 manufacturing sites and 50+ countries. In fiscal year 2024, Eastman reported record revenue of $9.38 billion with earnings per share of $9.50 and adjusted EPS of $10.80 (+18% over 2023), with segment margins reaching a record 24.0% (+200 basis points over 2023) and approximately $1.3 billion in operating cash flow. The company returned $679 million to stockholders through dividends and share repurchases. CEO Mark Costa has led Eastman's strategic transformation since 2014 toward specialty chemicals with higher margins and proprietary market positions. Eastman's most strategically significant initiative is its molecular recycling platform — using methanolysis technology to recycle polyester and thermoplastic waste back to virgin-equivalent materials, with the Kingsport Tennessee "Polyester Renewal" facility (one of the world's largest molecular recycling plants) producing RSPO-certified recycled content for premium consumer brands including Estée Lauder, L'Oréal, and Procter & Gamble seeking recycled content for packaging commitments.

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

70
Overall Score
90
#17
Category Rank
#9
77
AI Consensus
60
stable
Trend
stable
69
ChatGPT
99
73
Perplexity
99
65
Gemini
83
74
Claude
96
67
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.